Drug Trial Radar · NCT07175493
A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
158
Planned (sponsor's estimate)
Start
Nov 18, 2025
Primary completion
Nov 18, 2027
Study completion Nov 18, 2028
Sponsor
- Lead sponsor
- Keymed Biosciences Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of CM336 (BCMA/CD3 Bispecific Antibody) in the treatment of patients with relapsed or refractory autoimmune cytopenia
Conditions
- Autoimmune Cytopenia
- Immune Thrombocytopenia (ITP)
- Autoimmune Hemolytic Anemia
- Evans Syndrome
Interventions
CM336 InjectionBiological
subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 52 weeks
- Efficacy of CM336Time frame: 8 weeks
- Proportion of ITP subjects with a platelet count ≥ 50 × 10^9/L at least twice during the visit.Time frame: up to 52 weeks.
- Proportion of AIHA subjects with at least one instance of hemoglobin ≥ 100 g/L, and an increase ≥ 20 g/L compared to the baseline level.Time frame: up to 52 weeks.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Heping Hospital Affiliated to Changzhi Medical College
Changzhi, Shanxi, China · Recruiting
Blood Disease Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.